ASCO GI Highlights

Phase 3 Study of Tinengotinib Versus Physician’s Choice in Patients With FGFR-Altered, Chemotherapy- and FGFR Inhibitor-R/R CCA: Study Design of FIRST-308

ASCO GI Highlights

March 2024, Vol 5, No 1 — April 2, 2024

FIRST-308 is an open-label, phase 2, randomized, global, multicenter study that will evaluate the efficacy and safety of oral tinengotinib versus physician’s choice in patients with fibroblast growth factor receptor (FGFR)-altered, chemotherapy- and FGFR inhibitor-refractory/relapsed cholangiocarcinoma—this article will review the study’s eligibility criteria, primary endpoints, and more.

Characterization of Long-Term Survivors in TOPAZ-1

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.

MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.

Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.

Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.

Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements

Targeted Therapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.

Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC

Chemotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.

JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection

Chemotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.

Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202

Chemotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.

Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151

Immunotherapy, ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023

Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.

ASCO GI Highlights

Subscribe Today!

I'd like to receive:

Stay In The Know

ASCO GI Highlights

Page 2 of 5

Subscribe Today!

I'd like to receive:

Stay In The Know